Claudine Rancourt

Sherbrooke, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.

Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.

Journal: Breast cancer research : BCR
Published: August 03, 2017

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling.

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling.

Journal: Molecular cancer
Published: April 20, 2016

Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.

Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.

Journal: Clinical & experimental metastasis
Published: March 14, 2016

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.

Journal: BMC cancer
Published: March 16, 2015

MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling.

MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling.

Journal: American journal of cancer research
Published: October 28, 2014

Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail.

Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail.

Journal: International journal of oncology
Published: May 08, 2014

Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.

Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.

Journal: International journal of cancer
Published: March 20, 2014

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression.

Journal: BMC cancer
Published: October 23, 2013

Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis.

Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis.

Journal: Journal of ovarian research
Published: September 11, 2013

Role of malignant ascites on human mesothelial cells and their gene expression profiles.

Role of malignant ascites on human mesothelial cells and their gene expression profiles.

Journal: BMC cancer
Published: July 22, 2013

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis.

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis.

Journal: Journal of ovarian research
Published: September 06, 2012

Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis.

Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis.

Journal: Molecular cancer
Published: August 27, 2012
Showing 1-12 of 14

Last Updated: 09/26/2026